

Effect of Alkali Therapy on Vascular and Graft Function in Kidney Transplant Recipients

NCT05005793

Status	RECRUITING
Phase	Phase 4
Sponsor	University of Colorado, Denver
Enrollment	120 participants

Key Eligibility Criteria

Inclusion (11)

- Age 18-80 years
- Serum bicarbonate 16-24 mEq/L on 2 separate measurements (at least 1 day apart)
- Kidney transplant received 1 year prior to randomization
- eGFR \geq 45 ml/min/1.73m² by CKD-EPI equation
- Blood pressure \leq 130/80 mm Hg prior to randomization

... and 6 more (see full listing online)

Exclusion (11)

- Significant comorbid conditions that lead the investigator to conclude that life expectancy is less than 1 year
- Use of chronic daily oral alkali within the last 3 months (including sodium bicarbonate, calcium carbonate or baking soda)
- Uncontrolled hypertension
- Serum potassium \leq 3.3 or \geq 5.5 mEq/L at screening
- New York Heart Association Class 3 or 4 heart failure symptoms, known EF \leq 30%, or hospital admission for heart failure within the past 3 months

... and 6 more (see full listing online)

Locations (1 total)

University of Colorado, Aurora, Colorado, United States